Trial Profile
Phase I Study of the Safety of a Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs SP 0148 (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Adverse reactions
- 13 May 2019 Processed from abstract as full text is not available, have sent request to NZ interloans.
- 06 May 2019 Primary endpoint (Solicited injection site and systemic reactions (adverse events)) has been met as per results published in the Journal of Infectious Diseases.
- 06 May 2019 Results published in the Journal of Infectious Diseases